Sabitlenmiş Tweet
Genomics Cow
4.3K posts
Genomics Cow
@GenomicsCow
Original and probably disagreeable perspectives on genomics. Not sure when I'm joking and when I'm being serious. Opinions my own, not the herd’s.
Katılım Temmuz 2020
75 Takip Edilen3.2K Takipçiler
$NAUT Good to see they are starting commercial hires.
The VP's LinkedIn still says $SEER VP though, has she told them yet?😅
investors.nautilus.bio/news-releases/…
English
Just putting this out here again for Oxford Nanopore ppl
PS: don’t start by saying “but we had so much fun at AGBT”
Genomics Cow@GenomicsCow
Tips for thriving when there’s change in top management (ONT, Illumina…) -Don’t align yourself to the old leadership. You’ll be tarred with the same brush -Show no signs of duplicated effort between you and others. They are looking for area to trim down . . .
English
Roche offer flexibility to pick up small projects with Axelios
What this looks like and costs is unclear to me
But their instrument cost isn’t going to develop a large enough base to funnel projects upwards
And it’s not clear whether market dev is their interest anyway!
🐄
English
Element picked up a lot of small projects. But once the projects grew big the economics and throughput of NovaSeqs meant Illumina could swoop in on Element’s hard work
This may be part of why they need Vitari
English
Illumina raves on about their end-to-end workflows as it drives their key NovaSeq business👍
Actually one of their secret moats is their base of low- and mid-throughput platforms that help ppl’s genomics projects grow into NovaSeq-sized ones
English
“So you’re saying I wouldn’t have to worry about emulsion PCR anymore?”
Ultima rep: “What’s emulsion PCR?”
English
@OmicsOmicsBlog 10.10 a better fit, but suppose would have been too late to build towards a strong q4
English
After getting mocked for taking up speaking time last year without being able to disclose anything helpful, I wonder how Gustav is feeling - everyone either waiting for him to click the slides or just reading genomeweb 🐮
English
Roche’s value pricing model WOULDN’T have concluded $150/genome, but the team are factoring in a faster uptake than their traditional business model would have wanted from their huge investment
Exciting!
English
@Supergecko The problem for CosMx is they scarcely capture enough images through the z axis to get good 3d
Hopefully other 3d imaging platforms can use this software though 🤪
English
More new cool solutions for spatial omics introduced by Bruker: accurate 3D cell segmentation that correct cell assignment for ~20% transcripts, fully integrated AI to talk to your spatial results to enable disease experts to get true biology easily from data. #AGBTGM26
Lake Buena Vista, FL 🇺🇸 English
SMN1/2 isn’t collecting enough💰in many places for a standalone WGS
BUT many labs trying to consolidate legacy assays onto WGS, some which collect better💰to reduce TAT for all while being profitable, and for a long time high’ish volume SMN1/2 tests were hard to transfer over👍
Illumina@illumina
@UMCU_Intl Marcel Nelen: TruPath™ Genome is very easy to implement — and even in a notoriously complex region (SMN1/SMN2), it enabled a clear, confident answer in a challenging case — plus megabase scale phasing and clearer complex SV interpretation — one step closer to “one test fits all.” (4/11) #AGBTGM26
English
All the tech update news is out, except for Roche
If you struggled to fly out to Orlando for agbt, you can show up on Thursday now when the weather is good again 🐮
English
@dr_alphalyrae This here is a business model giving free rides for your data🐮
English
@MariosGeorgakis Lots of drug targets yes, lots of drugs no. But the leads are coming
That said, don’t forget many hits are not near genes, and many in genes haven’t proven to impact protein levels (genes themselves aren’t often the target etc etc)
English
While the genetic revolution promised to return thousands of drug targets, after massive investments in genomic and multi-omic datasets, we still struggle interpreting individual signals👇
Marios Georgakis@MariosGeorgakis
These comments in Nature Genetics on a GWAS signal for cerebral amyloid angiopathy at APOE are a great case study in the challenges of interpreting genetic associations even with abundant data. Worth reading for anyone interested in translating GWAS hits to drug targets👇
English
What made Jay Flatley are great speaker was that he could talk with his investors, staff, and customers differently and wonderfully
Jacob Thaysen seems a little less comfortable in front of his customers. Let’s see if he comes across more relatable at agbt this year than last
English
@OmicsOmicsBlog His was a weird take
Assets progressing through trials now based on better selection of patients through genotyping
Did we do WGS on them? No and who cares, we interpret genotyping now through the lens of population genomics and all sequencing has dropped becomes WGS has
English
Narrator: “the market for Minimal Residual Disease testing was $1.3B last year & for Multi-Cancer Early Detection another $1.5B; rare disease testing may have been $2B”
Bojan Tunguz@tunguz
The whole premise of cheaper genome sequencing was that it would lead to better individualized therapeuticals. I have yet to see *any* evidence that was the case. In my experience the practice of medicine has not changed an iota over the past 26 years.
English